Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Dent

Showing results (31-40 of 395) with videos related to

Pageof 40
Sort By:
Frontiers in Bioscience : a Journal and Virtual Library|January 30, 2002
Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survivalSteven Grant, Liang Qiao, Paul Dent
Cancer Biology & Therapy|June 23, 2005
DMC: novel celecoxib derivatives to rap cancerPaul Dent, Adly Yacoub, Steven Grant
Aging|July 19, 2016
Repurposing Tecfidera for cancerLaurence Booth, Mark Malkin, Paul Dent
Biochemical Pharmacology|June 7, 2020
Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancerLaurence Booth, Andrew Poklepovic, Paul Dent
Cancer Treatment and Research|December 17, 2002
The role of signal transduction pathways in drug and radiation resistanceSteven Grant, Paul B Fisher, Paul Dent
Journal of Cellular Biochemistry|February 14, 2007
Radiation-induced PARP activation is enhanced through EGFR-ERK signalingMichael P Hagan, Adly Yacoub, Paul Dent
DNA and Cell Biology|February 18, 2015
HSPA5/Dna K may be a useful target for human disease therapiesLaurence Booth, Jane L Roberts, Paul Dent
Seminars in Cancer Biology|October 24, 2019
The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinibLaurence A Booth, Jane L Roberts, Paul Dent
Expert Review of Anticancer Therapy|June 29, 2011
The potential of virus-based gene therapies for treatment of metastatic kidney cancerPaul Dent, David T Curiel, Paul B Fisher
Cancer Biology & Therapy|July 20, 2018
The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cellsLaurence Booth, Jane Roberts, Andrew Poklepovic, et al.
Pageof 40

Showing results (31-40 of 395) with videos related to

Sort By:
Pageof 40
Frontiers in Bioscience : a Journal and Virtual Library|January 30, 2002
Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survivalSteven Grant, Liang Qiao, Paul Dent
Cancer Biology & Therapy|June 23, 2005
DMC: novel celecoxib derivatives to rap cancerPaul Dent, Adly Yacoub, Steven Grant
Aging|July 19, 2016
Repurposing Tecfidera for cancerLaurence Booth, Mark Malkin, Paul Dent
Biochemical Pharmacology|June 7, 2020
Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancerLaurence Booth, Andrew Poklepovic, Paul Dent
Cancer Treatment and Research|December 17, 2002
The role of signal transduction pathways in drug and radiation resistanceSteven Grant, Paul B Fisher, Paul Dent
Journal of Cellular Biochemistry|February 14, 2007
Radiation-induced PARP activation is enhanced through EGFR-ERK signalingMichael P Hagan, Adly Yacoub, Paul Dent
DNA and Cell Biology|February 18, 2015
HSPA5/Dna K may be a useful target for human disease therapiesLaurence Booth, Jane L Roberts, Paul Dent
Seminars in Cancer Biology|October 24, 2019
The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinibLaurence A Booth, Jane L Roberts, Paul Dent
Expert Review of Anticancer Therapy|June 29, 2011
The potential of virus-based gene therapies for treatment of metastatic kidney cancerPaul Dent, David T Curiel, Paul B Fisher
Cancer Biology & Therapy|July 20, 2018
The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cellsLaurence Booth, Jane Roberts, Andrew Poklepovic, et al.
Pageof 40